ClinicalTrials.gg

Program

Fudotinib

Also written as “JYP0322 Tablets”, “JYP0322 tablets” and “JYP0322 50 mg qd”.

Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Lung Neoplasms, led by Guangzhou JOYO Pharma.

Furthest: phase 3, since Aug 19, 20253 company-led studies, 3 open or runningNext primary completion: Oct 31, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Guangzhou JOYO Pharma33 open or runningphase 3since Aug 19, 2025Nov 4, 2023Oct 31, 2027phase 3 · NCT07154368

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 4, 2023First study: phase 1 study in Lung NeoplasmsFirst studyNCT06128148 · 101 planned · China
  2. Aug 19, 2025Phase 3 study in Carcinoma, Non-Small-Cell LungNCT07154368 · 207 planned
  3. Sep 7, 2026Phase 3 study in Carcinoma, Non-Small-Cell LungNCT07816380 · 216 planned

Ahead

  1. Oct 31, 2027Primary completion: phase 3 study in Carcinoma, Non-Small-Cell LungNCT07154368
  2. Dec 30, 2028Primary completion: phase 3 study in Carcinoma, Non-Small-Cell LungNCT07816380

TargetBeta

ROS1 →read by rule
“An orally available selective inhibitor of the receptor tyrosine kinase c-ros oncogene 1 (ROS1), ”NCIt, by rule

Other programs on ROS1

ProgramCompanyFurthest phaseStudies
CrizotinibrulePfizerphase 431
taletrectinibruleNuvation Biophase 311
repotrectinibruleBristol-Myers Squibbphase 39
Cross-over to JYP0322ruleGuangzhou JOYO Pharmaphase 31
Radiosensitizer VS-101rulevspharmtech-co-ltdphase 22
ROS1/NTRK Inhibitor ANS03ruleavistone-biotechnology-co-ltdphase 11
SIM0518ruleSimcere Pharmaceutical Groupphase 11

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07816380Carcinoma, Non-Small-Cell Lung3Not yet recruitingDec 30, 2028216
NCT07154368Carcinoma, Non-Small-Cell Lung3Not yet recruitingOct 31, 2027207
NCT06128148Lung Neoplasms · China1RecruitingJun 30, 2026101

How it is read

Names in the registry

  • “JYP0322 Tablets”, 1 entry
  • “JYP0322 tablets”, 1 entry
  • “JYP0322 50 mg qd”, 1 entry
  • “JYP0322 100 mg qd”, 1 entry
  • “JYP0322 200 mg qd”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.